Ryan Ziemiecki
YOU?
Author Swipe
View article: mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and the Relationship to Productivity for Healthcare Workers and First Responders
mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and the Relationship to Productivity for Healthcare Workers and First Responders Open
Objectives To compare the percentage of participants that experienced any solicited systemic reactogenicity symptom after one dose of the updated 2024–2025 adjuvanted protein-based Novavax (NVX; JN.1) or Pfizer–BioNTech mRNA (PFZ; KP.2) CO…
View article: Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease Open
View article: Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study Open
View article: Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform
Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform Open
Introduction: In 2021, finerenone – a novel, selective nonsteroidal mineralocorticoid receptor antagonist – was approved in the USA to treat adults with chronic kidney disease (CKD) and type 2 diabetes (T2D). This study aimed to describe c…
View article: Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study
Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study Open
View article: Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines Open
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observationa…
View article: Reactogenicity Differences between COVID-19 Vaccines: A Pro-spective Observational Study in the United States and Canada
Reactogenicity Differences between COVID-19 Vaccines: A Pro-spective Observational Study in the United States and Canada Open
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational …
View article: Satisfaction With and Adherence to Off-Label Corticosteroids in Adolescents and Adults With Eosinophilic Esophagitis
Satisfaction With and Adherence to Off-Label Corticosteroids in Adolescents and Adults With Eosinophilic Esophagitis Open
Goals: We assessed satisfaction with and adherence to off-label corticosteroids in patients with eosinophilic esophagitis (EoE) in the United States. Background: EoE is a chronic inflammatory disease for which there are currently no US Foo…
View article: Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study Open
As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool to reduce the COVID-19 burden. Vaccine reactogenicity and the impact on work productivity/daily activities are recognized as contributing factors to vaccine hes…
View article: Protein Vaccine Demonstrates Less Reactogenicity than mRNA – A Real World Study
Protein Vaccine Demonstrates Less Reactogenicity than mRNA – A Real World Study Open
A prospective, observational study investigated the burden and impact of vaccine reactogenicity in adults from the United States and Canada who received an approved/authorized mRNA COVID-19 vaccine or the Novavax COVID vaccine as a booster…
View article: Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores
Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores Open
View article: Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting Open
These real-world studies do not suggest increased risks of hALI or sUTI, and they suggest a potential decreased risk of sUTI with dapagliflozin exposure compared with other GLDs.
View article: Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting Open
European Union Post-Authorisation Studies Register, EUPAS 11684; ClinicalTrials.gov, NCT02695082.
View article: Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study Open
This large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
View article: Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride
Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride Open
View article: Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350
Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350 Open
View article: Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study
Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study Open
View article: Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study
Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study Open
Background Blocking muscarinic receptors could have an effect on cardiac function, especially among elderly patients with overactive bladder ( OAB ). Study Objective To investigate the risk of cardiovascular (CV) events in users of antimus…
View article: P2.02-013 Costing Analysis of PROCLAIM Non–Small Cell Lung Cancer Trial Data
P2.02-013 Costing Analysis of PROCLAIM Non–Small Cell Lung Cancer Trial Data Open
View article: Outcomes following watchful waiting for stage <scp>II</scp>–<scp>IV</scp> follicular lymphoma patients in the modern era
Outcomes following watchful waiting for stage <span>II</span>–<span>IV</span> follicular lymphoma patients in the modern era Open
Summary To examine the effectiveness of an initial management strategy of watchful waiting for follicular lymphoma ( FL ) in clinical practice, we compared outcomes for patients diagnosed 2004–2007 in the United States initially managed wi…